The efficacy and safety of irinotecan cisplatin and mitomycin chemotherapy in sunitinib pre-treated metastatic clear cell renal cancer.

Abstract

BACKGROUND:

Sunitinib is widely used as first-line treatment for metastatic clear cell renal cancer (MCRC). No reports are known of treatment after sunitinib failure. As irinotecan, cisplatin, and mitomycin-C (IPM) chemotherapy has been reported to influence MCRC after progression on cytokine therapy, we report on the outcome of 11 patients treated with IPM after sunitinib failure.

PATIENTS AND METHODS:

Eleven patients with progression of disease on sunitinib therapy were treated with 4, monthly cycles of monthly IPM.

RESULTS:

Nine out of 11 patients progressed during IPM therapy. The median time to progression was 1.4 months (95% CI: 0.7-2.1 months), while the overall survival was 4.2 months (95% CI: 0.9-2.3). Overall 10 patients have died of progressive renal cancer. One patient had a radiological response to therapy and remains progression free 11 months after treatment. Four of the 10 patients required a dose reduction for grade 3 or 4 toxicities.

CONCLUSIONS:

IPM alone does not appear to benefit patients with MCRC who previously progressed during sunitinib therapy. The median progression-free survival and overall survival for these patients is short.

• Authors: Thomas Powles, Siobhan McFaul, Justin Stebbing, Peter Wilson, Tim Oliver, Naomi Tranter, Jonathan Shamash
• Journal: OncoTargets and therapy (Onco Targets Ther) Vol. 1 Pg. 35-9 (Sep 01 2008) ISSN: 1178-6930 [Print] New Zealand
• PMID: 21127750 (Publication Type: Journal Article)